RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
RAPT Therapeutics - Stock

RAPT Therapeutics Equity 2024

RAPT Therapeutics Equity

147.04 M USD

Ticker

RAPT

ISIN

US75382E1091

WKN

A2PNYQ

In 2024, RAPT Therapeutics's equity was 147.04 M USD, a -40.03% increase from the 245.2 M USD equity in the previous year.

RAPT Therapeutics Aktienanalyse

What does RAPT Therapeutics do?

Rapt Therapeutics Inc. is an emerging pharmaceutical company that was originally founded in 2015 under the name "FLX Bio". The company is based in San Francisco, California. Rapt is the name of the biological process that the company uses to identify and develop drug candidates. Rapt Therapeutics specializes in developing innovative immunotherapies for cancer treatment. The goal is to harness the power of the immune system to support the body in fighting cancer. The company focuses on developing prophylactic cancer vaccines and immunotherapies that aim to directly combat cancer cells and strengthen the body's defenses. The company's business model is based on an innovative technology platform that is able to identify antibodies and other molecules that activate the RAPT process, which is important for combating cancer cells. With this technology, Rapt Therapeutics can quickly and accurately identify potential drug candidates that are suitable for the development of cancer immunotherapies. At the time of its founding, Rapt primarily focused on developing immunotherapeutics for solid tumors, a type of cancer that originates in a specific tissue in the body and does not spread to adjacent tissues or organs. However, the company has since expanded its portfolio to include the development of therapeutics for hematological cancers such as leukemia and lymphoma. Rapt Therapeutics employs a pipeline-based research strategy. The pipeline-based research strategy means that Rapt Therapeutics develops a variety of drug candidates targeting different disease indications. The drug candidates are then tested in different phases of clinical development to evaluate their efficacy and safety. To date, Rapt Therapeutics has four drug candidates in clinical development. The first candidate, RPT193, is currently being tested in phase 1 clinical trials for the treatment of various solid tumors. The second candidate, RPT835, is currently in preclinical development and targets the treatment of leukemia. The third candidate, FLX475, is also in preclinical development and targets the treatment of multiple sclerosis. The fourth candidate, FLX475, is currently in phase 1 clinical trials and targets the treatment of certain solid tumors. In addition, Rapt Therapeutics has also entered into a number of partnerships with other pharmaceutical companies. In 2018, Rapt Therapeutics signed a strategic collaboration with AstraZeneca to accelerate the development of RPT193. Under this collaboration, AstraZeneca will test RPT193 in clinical trials. In 2019, Rapt Therapeutics entered into a research and development collaboration with Hanmi Pharmaceutical Co. Ltd. to accelerate the discovery, development, and commercialization of drug candidates for cancer and other diseases. Rapt Therapeutics is pursuing a long-term strategy to become a leading company in immunotherapy development. By continuing its research and development of cancer immunotherapies, Rapt has the potential to improve the lives of millions of people suffering from cancer and other serious diseases. RAPT Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing RAPT Therapeutics's Equity

RAPT Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding RAPT Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating RAPT Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

RAPT Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in RAPT Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about RAPT Therapeutics stock

What is the equity of RAPT Therapeutics this year?

RAPT Therapeutics has equity of 147.04 M USD this year.

What was the equity of RAPT Therapeutics compared to the previous year?

The equity of RAPT Therapeutics has increased/decreased by -40.03% decreased compared to the previous year.

What impact does a high equity have on investors of RAPT Therapeutics?

A high equity is advantageous for investors of RAPT Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of RAPT Therapeutics?

A low equity can be a risk for investors of RAPT Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of RAPT Therapeutics affect the company?

An increase in equity of RAPT Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of RAPT Therapeutics affect the company?

A reduction in equity of RAPT Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of RAPT Therapeutics?

Some factors that can affect the equity of RAPT Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of RAPT Therapeutics so important for investors?

The equity of RAPT Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can RAPT Therapeutics take to change the equity?

To change equity, RAPT Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does RAPT Therapeutics pay?

Over the past 12 months, RAPT Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, RAPT Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of RAPT Therapeutics?

The current dividend yield of RAPT Therapeutics is .

When does RAPT Therapeutics pay dividends?

RAPT Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of RAPT Therapeutics?

RAPT Therapeutics paid dividends every year for the past 0 years.

What is the dividend of RAPT Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is RAPT Therapeutics located?

RAPT Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von RAPT Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of RAPT Therapeutics from 7/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/7/2024.

When did RAPT Therapeutics pay the last dividend?

The last dividend was paid out on 7/7/2024.

What was the dividend of RAPT Therapeutics in the year 2023?

In the year 2023, RAPT Therapeutics distributed 0 USD as dividends.

In which currency does RAPT Therapeutics pay out the dividend?

The dividends of RAPT Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The RAPT Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von RAPT Therapeutics

Our stock analysis for RAPT Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of RAPT Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.